Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 400,693 | 2,379 | 0 | 0 | 0 |
| Marketable Securities | 10,646 | 33,712 | 0 | 0 | 0 |
| TOTAL | $411,754 | $36,233 | $0 | $0 | $0 |
| Non-Current Assets | |||||
| PPE Net | 100 | 71 | N/A | N/A | N/A |
| Other Non-Current Assets | 0 | 212 | 0 | 0 | 0 |
| TOTAL | $100 | $283 | $N/A | $N/A | $N/A |
| Total Assets | $411,854 | $36,516 | $0 | $0 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,033 | 1,399 | 0 | 0 | 0 |
| Accrued Expenses | 1,673 | 931 | 0 | 0 | 0 |
| TOTAL | $3,706 | $2,330 | $0 | $0 | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 142 | 45,501 | 0 | 0 | 0 |
| TOTAL | $142 | $45,501 | $N/A | $N/A | $N/A |
| Total Liabilities | $3,848 | $47,831 | $0 | $0 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 55,617 | N/A | N/A | N/A | N/A |
| Common Shares | 6 | 1 | 0 | 0 | 0 |
| Retained earnings | -17,437 | -11,923 | 0 | 0 | 0 |
| Other shareholders' equity | 2 | 156 | 0 | 0 | 0 |
| TOTAL | $408,006 | $-11,315 | $0 | $0 | $0 |
| Total Liabilities And Equity | $411,854 | $36,516 | $0 | $0 | $0 |